Eastern Network of Cancer Immunological Therapy

ENCIT (Eastern Network of Cancer Immunological Therapy) is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative immune cell therapies for solid tumors. The company leverages its proprietary technology platforms to engineer CAR-T and TCR-T cells designed to overcome the immunosuppressive microenvironment of solid cancers. ENCIT's pipeline includes several candidates targeting high-value antigens such as GPC3 and Claudin 18.2, with multiple programs currently undergoing clinical evaluation. The company is uniquely positioned through its close integration with a network of clinical centers, facilitating the rapid translation of laboratory research into clinical applications. ENCIT aims to provide effective treatment options for patients with refractory or metastatic cancers through advanced cellular immunotherapy.